Biocon's 'oral human insulin' is to soon go on Phase I trial. It maybe as early as a month – declared the MD of Biocon, Ms.Kiran Mazumdar Shaw
Biocon's 'oral human insulin' is to soon go on Phase I trial. It maybe as early as a month – declared the MD of Biocon, Ms.Kiran Mazumdar Shaw.
Ms.Shaw was speaking at the conference organized in Chennai by Madras Diabetes Research Foundation(MDRF) on awards for innovation and R&D. There are close to 34 million diabetics in India and any research related to diabetes should always bear this in mind and develop products accordingly.Ms.Shaw said” “India has a tremendous potential to leverage her intellectual capital to create intellectual wealth innovation in all fields of enterprise and this needs to be unleashed.” Shaw felt that innovation was the strongest currency in a knowledge economy. What was required was convergence of clinical practice with research. India has a tremendous opportunity with its huge variety of patient load. India has still to take advantage of this aspect.
Ms. Shaw felt that the Biotec Industry in India would soon be able to match the Infotech sector with many new companies now joining in.
The two-day conference was organized by MDRF with Karolinska Institute, Sweden.
